A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of ACZ885 (Anti-interleukin-1beta Monoclonal Antibody) With Three Different Dose Regimens in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate Including 76-week and 96-week Extensions
Latest Information Update: 06 Oct 2021
Price :
$35 *
At a glance
- Drugs Canakinumab (Primary) ; Canakinumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Novartis
- 01 Dec 2008 Actual study completion date changed from October 2008 to September 2008 as reported by ClinicalTrials.gov.
- 01 Dec 2008 Actual study completion date changed from October 2008 to September 2008 as reported by ClinicalTrials.gov.
- 01 Dec 2008 Actual study completion date changed from October 2008 to September 2008 as reported by ClinicalTrials.gov.